Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled trial of alogliptin, albuterol, and nilvadipine in moderate Parkinson's disease
ACTRN12620000560998Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alogliptin, salbutamol and nilvadipine in Parkinson's disease (PD) (4 arms), sponsored by University of Sydney. Primary endpoint: Change in motor symptom progression measured by MDS-UPDRS in the OFF usual PD medication state. Started Jun 2020; status: completed.
02
Drugs
alogliptinsalbutamolnilvadipine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12620000560998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000560998.